Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation, and survival. Overexpression and overactivation of …

Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was
scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin …

Objectives. Inhibition of calcium‐/calmodulin‐(CaM‐) dependent kinase II (CaMKII) is
correlated with epilepsy. However, the specific mechanism that underlies learning and …

BRAF is the most common serine-threonine protein kinase and regulates signal transduction
from RAS to MEK inside the cell. The BRAF is a highly active isoform of RAF kinase. BRAF …

Cancer incidence is rapidly growing. Solid tumors are responsible for a majority of cancers.
Recently, molecular-targeted agents have played a significant role in cancer treatment. Ras …

Primary cutaneous and mucosal melanoma shows a wide histological spectrum. The correct
diagnosis depends upon the demonstration of melanocytic differentiation by recognition of …

Pax6, a transcription factor and multifunctional protein, changes during aging. It also
interacts with regulator proteins involved in cell metabolism and survival signalling pathways …

Abstract BRAF alterations, including V600E and non‐V600E mutations and fusions, in soft
tissue sarcoma (STS) have been identified in a limited case series. Here, we aimed to …